Resolution Therapeutics

📢 Resolution Therapeutics today announces £63.5 Million Series B Financing 📢   The financing, led by Syncona Limited will be used to advance our lead asset RTX001, a pro-regenerative macrophage therapy for end-stage liver disease, into the Phase I/II EMERALD study ✨   Paul Sekhri has joined as Chair of the Board of Directors, with over 35 years of experience in the life science industry. Pauls leadership will be invaluable as we continue to grow 🚀   Learn more about the Series B financing in the full press release in the first comment below.

Resolution Therapeutics is attending #BIOEurope. Join our CEO Amir Hefni and our VP of Strategy & Operations Victor Dillard in Stockholm, Sweden, November 4–6, 2024, to connect and learn more about our mission to pioneer regenerative macrophage therapy in inflammatory and fibrotic diseases. #macrophages #liverdisease #fibrosis

Resolution Therapeutics Chief Manufacturing and Technical Operations Officer Amol Ketkar recently spoke on a panel at BioProcess International 2024, alongside Eminence Lead of NextGen Therapies at Deloitte Consulting, Omkar Kawalekar, CTO Health Technologies at imec, Peter Peumans, and CEO of Orgenesis Inc., Vered Caplan. You can read more on Amol and the rest of the panel's thoughts via the link to the article here: https://lnkd.in/ehH7XEZe #CGT #manufacturing #celltherapy #bioprocessinternational

Thank you Amy Brown for visiting our offices to discuss our recent £63.5 million Series B financing!   In the latest BiotechTV episode, our CEO, Amir Hefni, shares how Resolution Therapeutics plans to use this funding to advance our pro-regenerative macrophage cell therapy, aimed at promoting organ repair to treat end-stage liver disease.   See the preview below or see the full episode here: https://lnkd.in/gTzXMrDQ

For World Mental Health Day, Mental health at work, Resolution Therapeutics stands together in raising awareness about the importance of a healthy working environment.  Our commitment to creating a positive, safe, and inclusive workplace culture where every individual can thrive is the cornerstone of our foundation. #OneTeam #ResolutionTherapeutics #WorldMentalHealthDay #MentalHealthAtWork 

For World Mental Health Day, Mental health at work, Resolution Therapeutics stands together in raising awareness about the importance of a healthy working environment.  Our commitment to creating a positive, safe, and inclusive workplace culture where every individual can thrive is the cornerstone of our foundation. #OneTeam #ResolutionTherapeutics #WorldMentalHealthDay #MentalHealthAtWork 

Biotech spinout Resolution Therapeutics has raised £63.5 million in Series B investment led by Syncona Limited for its macrophage cell therapy for end-stage liver disease.The company was co-founded in 2020 by Professor Stuart Forbes of the Institute for Regeneration and Repair. Dr Andrea Taylor, CEO of Edinburgh Innovations, which supported Professor Forbes through a decade of macrophage research and commercialisation, said: “The journey from lab to clinic is long and arduous and we are delighted to see Resolution approaching clinical stage. “There is currently no treatment for liver cirrhosis, apart from a liver transplant and a life on immunosuppressants, and this therapy brings cautious hope for those suffering from this neglected disease, and potentially other inflammatory conditions too.” Read more ➡️ eil.ac/ResolutionSeriesB/L #biotech #investment #liver cirrhosis #celltherapy #liverdisease #macrophagecelltherapy

Thank you Greig Cameron for featuring our £63.5 million Series B financing as a lead story in The Times!   This financing is a major milestone for Resolution, and we look forward to updating everyone on our EMERALD I/II Study as it unfolds.   Read the feature here: https://lnkd.in/eSxkC_E6

Here's an interesting idea: cell therapy for end-stage liver disease. Resolution Therapeutics is boosting the anti-inflammatory and anti-fibrotic powers of macrophages to clean up and heal liver cirrhosis. First patient to be dosed later this year. I talked to CEO Amir Hefni to learn more for my story in Endpoints News. https://lnkd.in/evxJaBiH

We are thrilled to be attending American Association for the Study of Liver Diseases (AASLD) ‘The Liver Meeting’ in San Diego this November ☀️ and presenting novel data on the exciting potential of macrophages in end-stage liver disease. This marks a significant milestone for Resolution as the The University of Edinburgh presents clinical data highlighting the impact of macrophage cell therapy in cirrhosis and we share preclinical data for our lead candidate, RTX001, cleared to enter the clinic in the UK. 🎤 For full details on the presentations, see the press release in the comments below. Reach out if you would like to learn more about the company or to meet a member of the team at #AASLD2024! 🎉 #EASL #TheLiverMeeting #LiverDisease